Why Coronado Biosciences Is Poised to Plunge
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Coronado Biosciences has received a distressing two-star ranking.
With that in mind, let's take a closer look at Coronado and see what CAPS investors are saying about the stock right now.
Burlington, Mass. (2006)
Chairman/CEO Harlan Weisman
Return on Capital (average, past 3 years)
$40.2 million / $14.2 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 15% of the 20 members who have rated Coronado believe the stock will underperform the S&P 500 going forward.
Whipworm eggs to treat autoimmune disease might sound completely reasonable to some people, but I see it as farfetched to the border of insanity. If you wonder why high level executives and scientists would spend years pursuing a completely irrational scientific endeavor, my answer would be that I don't know but I see it happen all the time. The fact that Coronado management is confident does not make me confident. Pull out all the pretty epidemiologically colored world maps you want, I will snarf my corn flakes if I open up my watchlist one morning and find out this works. Topline results from the TRUST-1 phase II trial of the magic beans in ulcerative colitis are expected in the second half of 2013, so we don't have too long to wait.
While you can certainly make quick gains in speculative biotech stocks, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Coronado Biosciences Is Poised to Plunge originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.